4.1 Article

Small-Molecule Inhibitors of the c-Fes Protein-Tyrosine Kinase

期刊

CHEMISTRY & BIOLOGY
卷 19, 期 4, 页码 529-540

出版社

CELL PRESS
DOI: 10.1016/j.chembiol.2012.01.020

关键词

-

资金

  1. National Institutes of Health [CA123756, GM079575, CA130876]
  2. Canadian Institutes for Health Research
  3. Canadian Foundation for Innovation
  4. Genome Canada through the Ontario Genomics Institute
  5. GlaxoSmithKline
  6. Karolinska Institute
  7. Knut and Alice Wallenberg Foundation
  8. Ontario Innovation Trust
  9. Ontario Ministry for Research and Innovation
  10. Merck Co., Inc.
  11. Novartis Research Foundation
  12. Swedish Agency for Innovation Systems
  13. Swedish Foundation for Strategic Research
  14. Wellcome Trust

向作者/读者索取更多资源

The c-Fes protein-tyrosine kinase modulates cellular signaling pathways governing differentiation, the innate immune response, and vasculogenesis. Here, we report the identification of types I and II kinase inhibitors with potent activity against c-Fes both in vitro and in cell-based assays. One of the most potent inhibitors is the previously described anaplastic lymphoma kinase inhibitor TAE684. The crystal structure of TAE684 in complex with the c-Fes SH2-kinase domain showed excellent shape complementarity with the ATP-binding pocket and a key role for the gatekeeper methionine in the inhibitory mechanism. TAE684 and two pyrazolopyrimidines with nanomolar potency against c-Fes in vitro were used to establish a role for this kinase in osteoclastogenesis, illustrating the value of these inhibitors as tool compounds to probe the diverse biological functions associated with this unique kinase.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据